The U.S. startup acquisition landscape is experiencing a remarkable surge, with 2026 projected to set a new record in M&A spending. According to a Crunchbase analysis, acquirers have already invested at least $119.8 billion in private, venture-backed companies this year, significantly bolstered by SpaceX's unprecedented $60 billion acquisition of AI coding tool Cursor and its parent company, Anysphere. This monumental deal, announced in April and finalized following SpaceX's IPO, marks the largest startup acquisition in history, nearly doubling the previous record held by Google's $32 billion purchase of Wiz. Other notable transactions include Eli Lilly's strategic acquisitions in the biotech sector, which have also contributed to the robust M&A activity this year.
Biotech has emerged as a particularly vibrant segment, with Eli Lilly leading the charge by acquiring Kelonia Therapeutics for up to $7 billion, marking the largest acquisition of a venture-backed biotech firm in recent years. Lilly's other significant purchases include Orna Therapeutics and Ajax Therapeutics, further solidifying its position in the biotech space. Additionally, Capital One's acquisition of Brex for $5.15 billion and Qualcomm's recent $4 billion purchase of Modular highlight the diverse range of sectors witnessing substantial M&A activity.
As the second quarter draws to a close, the potential for additional high-profile deals looms large, indicating that 2026 will likely continue this trend of aggressive spending in startup acquisitions. The current trajectory suggests a dynamic environment for investors and founders alike, as the market remains ripe for strategic consolidation and innovation-driven growth.
Biotech has emerged as a particularly vibrant segment, with Eli Lilly leading the charge by acquiring Kelonia Therapeutics for up to $7 billion, marking the largest acquisition of a venture-backed biotech firm in recent years. Lilly's other significant purchases include Orna Therapeutics and Ajax Therapeutics, further solidifying its position in the biotech space. Additionally, Capital One's acquisition of Brex for $5.15 billion and Qualcomm's recent $4 billion purchase of Modular highlight the diverse range of sectors witnessing substantial M&A activity.
As the second quarter draws to a close, the potential for additional high-profile deals looms large, indicating that 2026 will likely continue this trend of aggressive spending in startup acquisitions. The current trajectory suggests a dynamic environment for investors and founders alike, as the market remains ripe for strategic consolidation and innovation-driven growth.
Source: Crunchbase
